Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (198)	11/5/1997 5:29:00 PM
From: lucky	Respond to of 371

Annual Meeting Well its only about 15 minutes away, so I thought I would attend the annual meeting today. This is how I remember it: General impression was extremely positive. Products: Dr. Goldenberg discussed various new uses for existing products and the developments of those products (See today's announcement). Overall the products available and the product pipeline appear very strong. Sales: Discussed generally Mallincrodt(sp?) being replaced by a new partner due to under performance. Discussed Immu's new sales force and why, even at a samll number that sales force can be more effective than a much larger sales force which does not focus on Immu products. The approach and argument was logical. CFO indicated that there is only enough money for next fiscal year. Financing was discussed generally in the usual terms. Partners/Takeover: Strategic/Sales partners are in the works - need to resolve Mallincrodt issue. Asked the Dr. if the company's independence was an issue. He responded by saying that the company will remain independent. Coverage: In discussions with Wall Street. (That is all he would say.)